Parnell Pharmaceuticals Holdings Net Profit Margin 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings net profit margin from 2014 to 2018. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Parnell Pharmaceuticals Holdings Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2018-03-31 |
$0.01B |
$-0.01B |
-58.33% |
| 2016-12-31 |
$0.01B |
$-0.02B |
-107.14% |
| 2016-09-30 |
$0.01B |
$-0.02B |
-115.38% |
| 2015-12-31 |
$0.01B |
$-0.01B |
-100.00% |
| 2015-09-30 |
$0.01B |
$0.00B |
-44.44% |
| 2015-06-30 |
$0.01B |
$0.00B |
-42.86% |
| 2014-12-31 |
$0.00B |
$-0.01B |
-150.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
